These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 21352073)

  • 1. Treatment of non-alcoholic fatty liver disease with focus on emerging drugs.
    Marchesini G; Moscatiello S; Agostini F; Villanova N; Festi D
    Expert Opin Emerg Drugs; 2011 Mar; 16(1):121-36. PubMed ID: 21352073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expert opinion on current therapies for nonalcoholic fatty liver disease.
    Della Corte C; Alisi A; Iorio R; Alterio A; Nobili V
    Expert Opin Pharmacother; 2011 Aug; 12(12):1901-11. PubMed ID: 21639814
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The role of medications for the management of patients with NAFLD.
    Mazzella N; Ricciardi LM; Mazzotti A; Marchesini G
    Clin Liver Dis; 2014 Feb; 18(1):73-89. PubMed ID: 24274866
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Weight loss: cornerstone in the treatment of non-alcoholic fatty liver disease.
    Tilg H; Moschen A
    Minerva Gastroenterol Dietol; 2010 Jun; 56(2):159-67. PubMed ID: 20485253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Therapeuric aspects of NAFLD. A literature review].
    Tapia NC; Avila FI; Leiva JG; Ramos MH; Avila JF; Uribe M
    Rev Gastroenterol Mex; 2006; 71(4):487-95. PubMed ID: 17542283
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Emerging drugs for non-alcoholic steatohepatitis.
    Tomeno W; Yoneda M; Imajo K; Ogawa Y; Kessoku T; Saito S; Eguchi Y; Nakajima A
    Expert Opin Emerg Drugs; 2013 Sep; 18(3):279-90. PubMed ID: 23848366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-alcoholic fatty liver disease from pathogenesis to management: an update.
    Musso G; Gambino R; Cassader M
    Obes Rev; 2010 Jun; 11(6):430-45. PubMed ID: 19845871
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Non-alcoholic fatty liver disease in obese adults: clinical aspects and current management strategies.
    Pallayova M; Taheri S
    Clin Obes; 2014 Oct; 4(5):243-53. PubMed ID: 25825857
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Focus on emerging drugs for the treatment of patients with non-alcoholic fatty liver disease.
    Federico A; Zulli C; de Sio I; Del Prete A; Dallio M; Masarone M; Loguercio C
    World J Gastroenterol; 2014 Dec; 20(45):16841-57. PubMed ID: 25492998
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review article: current management of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    Younossi ZM
    Aliment Pharmacol Ther; 2008 Jul; 28(1):2-12. PubMed ID: 18410557
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pentoxifylline and melatonin in combination with pioglitazone ameliorate experimental non-alcoholic fatty liver disease.
    Zaitone S; Hassan N; El-Orabi N; El-Awady el-S
    Eur J Pharmacol; 2011 Jul; 662(1-3):70-7. PubMed ID: 21549113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of patients with non-alcoholic fatty liver disease: current views and perspectives.
    Federico A; Trappoliere M; Loguercio C
    Dig Liver Dis; 2006 Nov; 38(11):789-801. PubMed ID: 16750661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of weight loss on nonalcoholic fatty liver disease.
    Patel AA; Torres DM; Harrison SA
    J Clin Gastroenterol; 2009; 43(10):970-4. PubMed ID: 19727004
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nonalcoholic fatty liver disease: current and potential therapies.
    Ibrahim MA; Kelleni M; Geddawy A
    Life Sci; 2013 Feb; 92(2):114-8. PubMed ID: 23159641
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic fatty liver disease and lipids.
    Wierzbicki AS; Oben J
    Curr Opin Lipidol; 2012 Aug; 23(4):345-52. PubMed ID: 22617751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current treatment of non-alcoholic fatty liver disease.
    Ahmed MH; Byrne CD
    Diabetes Obes Metab; 2009 Mar; 11(3):188-95. PubMed ID: 18564173
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin resistance and oxidative stress interdependency in non-alcoholic fatty liver disease.
    Videla LA; Rodrigo R; Araya J; Poniachik J
    Trends Mol Med; 2006 Dec; 12(12):555-8. PubMed ID: 17049925
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Review article: Drug therapy for non-alcoholic fatty liver disease.
    Comar KM; Sterling RK
    Aliment Pharmacol Ther; 2006 Jan; 23(2):207-15. PubMed ID: 16393299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease: pharmacologic and surgical options.
    Parikh N; Ahmad J
    Gastroenterol Clin North Am; 2011 Sep; 40(3):541-59. PubMed ID: 21893273
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current best treatment for non-alcoholic fatty liver disease.
    Angulo P
    Expert Opin Pharmacother; 2003 May; 4(5):611-23. PubMed ID: 12739988
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.